Abstract P4-14-10: Pertuzumab overcomes chemotherapy/trastuzumab resistance in ER+/Her2+ tumors classified as luminal functional subtype by the 80-gene BluePrint assay in the prospective neo-adjuvant breast registry symphony trial (NBRST)
Publication/Presentation Date
2-2016
Volume
76
Issue
4
Published In/Presented At
Disciplines
Medicine and Health Sciences
Department(s)
Department of Surgery
Document Type
Article
COinS